Novo Nordisk's once-weekly insulin marches on after hitting goals in pair of phase 3 trials

Novo Nordisk has added more threads to the data tapestry it is weaving in support of the once-weekly insulin icodec, dropping positive top-line results from two phase 3a studies in its six-part ONWARDS program.